India CEOs On Automated Plants, New Modalities, Tackling 'The Great Talent Reshuffle'
The top leadership of Cipla, Dr Reddy’s Laboratories, Zydus Cadila, Sun Pharmaceutical Industries and Lupin discuss automation roadmaps, strategies for a play in new modalities and talent acquisition and retention amid the global "great resignation."
You may also be interested in...
C-suite executives from Sun Pharma, Zydus, Dr Reddy’s, Biocon, Piramal and Bharat Serums discuss future growth drivers as the generics opportunity shrinks. Favorable patent box policies, open-source innovation and areas like gene therapy and orphan diseases feature among ideas thrown up.
McKinsey senior partner Joseph Hughes outlines the shape of things to come as new technologies transform life sciences manufacturing, while new modalities around cell-, gene- and RNA-based therapeutics could have “profound implications” on global operations networks.
Keep your eyes on Asia, both for groundbreaking innovation and huge market opportunities, says Alex Gorsky, executive chairman of Johnson & Johnson. He also outlines exciting possibilities as biology and chemistry are being “fundamentally digitized.”